Medical/Pharmaceuticals
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health
Innovative sample collection methods developed through Gates Foundation-funded grant enable high-quality metabolomics biomarker discovery in populations from low- and middle-income countries MORRISVILLE, N.C., Aug. 25, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solut...
2026-08-25 21:00
525
WuXi Biologics Reports Strong Profitable Growth in H1 2026
* Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) * IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds * EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted...
2026-08-25 20:45
1406
Fosun Pharma Announces 2026 Interim Results
Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company r...
2026-08-25 20:44
1774
MATELASER Unveils MATEROBOT®, a Next-Generation Six-Axis Laser Therapy Robot With a Detachable Portable Laser System
Powered by the FDA-cleared X1 PERFORMANCE ULTRA, the modular platform combines robotic automation, triple-wavelength laser therapy and closed-loop thermal control MIAMI, Aug. 25, 2026 /PRNewswire/ -- MATELASER, INC., a U.S.-based developer of advanced laser therapy and rehabilitation technologie...
2026-08-25 20:00
620
Innovent Announces 2026 Interim Results and Business Updates
Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comm...
2026-08-25 18:15
1221
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
BEIJING, Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd.("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners (...
2026-08-25 18:14
778
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J., Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Admini...
2026-08-25 18:00
445
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
TAIPEI, Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombinati...
2026-08-25 14:56
615
Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
* Expands global portfolio beyond HIFU and MRF to include MNRF, laser, and dermabrasion devices, strengthening its medium- to long-term growth foundation * 1H26 Exports, excluding shipments to its Brazilian subsidiary, grew 29% year over year, underscoring continued growth across global market...
2026-08-25 12:26
927
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Sin...
2026-08-25 09:15
641
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-25 08:30
991
Dimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound Care
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more accessible...
2026-08-25 01:50
884
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
* Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) * Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increas...
2026-08-24 20:35
1949
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...
2026-08-24 15:01
979
INDONESIAN HEALTHCARE TRAVEL TO MALAYSIA HITS RECORD RM2.2 BILLION AS MHX RETURNS TO YOGYAKARTA
YOGYAKARTA, Indonesia, Aug. 24, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) once again strengthened Malaysia's presence in Indonesia through MHX Yogyakarta 2026, held from 20 to 23 August 2026 at the Grand Atrium, Pakuwon Mall Jogja. The four-day event came on the back of a rec...
2026-08-24 13:31
1157
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
2026-08-24 12:40
916
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...
2026-08-24 11:05
1023
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
2026-08-24 09:54
2094
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-24 09:00
1963
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...
2026-08-24 08:00
1196
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 314 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
13355
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
13112
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
11162
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
6676